EXCLUSIVE INTERVIEW

2nd Annual

Novel Ingredients for Infant Formula & Nutrition Summit

-June 10-12, 2025 | Boston, MA-

Tim Lambers
Senior Scientist, Early Life Nutrition
FrieslandCampina Ingredients

1. How is FrieslandCampina Ingredients innovating novel bioactive ingredients for application in infant formula?

With over 80 years of expertise in early life nutrition, FrieslandCampina Ingredients is deeply committed to supporting the health and development of infants and young children during their most critical growth phases. Our innovation process begins with a deep understanding of both infant needs and parental priorities—where gut health, immunity, and brain development consistently emerge as top concerns. Our comprehensive portfolio, which makes up approximately 95% of an infant formula, includes key ingredients such as galacto-oligosaccharides (GOS), milk fat globule membrane (MFGM), lactoferrin, milk fat, whey proteins, and hydrolysates.

2. What benefits do these ingredients offer in the context of infant formula?

Our portfolio is rich in bioactive proteins, hydrolysates, and oligosaccharides, all designed to meet the evolving needs of our customers. These innovations are driven by our in-house R&D or through collaborative development with partners. For instance, our Vivinal® MFGM is produced in a mildy manner for dry-blend applications, preserving heat-sensitive components like immunoglobulins (IgG) and lactoferrin.

> *Navigating the global regulatory environment is one of the most significant challenges in the infant formula industry*

This ensures the delivery of high-quality protein ingredients that support immune health in infants.

3. How are your preclinical analytics supporting these innovations, particularly for regulatory dossier submissions?

Infant formula is one of the most regulated food categories. Our ingredients are developed with deep scientific and regulatory insight. For example, by analyzing MFGM's components—like sphingomyelin, IgG, IgA, lactoferrin, and osteopontin—we help brands meet standards, differentiate products, and communicate benefits clearly. Our regional RA experts ensure we stay aligned with evolving regulations.

4. How are you navigating the global regulatory landscape and preparing for future changes?

Navigating the global regulatory environment is one of the most significant challenges in the infant formula industry. As one of the most

Continue reading

EXCLUSIVE INTERVIEW

2nd Annual
Novel Ingredients for Infant Formula & Nutrition Summit

-June 10-12, 2025 | Boston, MA-

Tim Lambers
Senior Scientist, Early Life Nutrition
FrieslandCampina Ingredients

tightly regulated food categories, infant formula must meet rigorous safety, labeling, and nutritional standards—rightfully so, given the vulnerability of the population it serves.

Our ingredients are backed by extensive research and developed in close collaboration with our global scientific network. This long-standing expertise allows us to meet both regulatory requirements and parental expectations. Through detailed compositional reviews, we help brands clearly communicate the benefits of their products. For example, MFGM contains a complex matrix of lipids—such as sphingomyelin—and bioactive proteins like IgG, IgA, lactoferrin, osteopontin, and alpha-lactalbumin. Characterizing these components not only supports regulatory approval but also enables product differentiation and premium positioning. With regulatory affairs experts in every region, we stay closely aligned with evolving regulations and maintain strong relationships with local authorities.

5**. What are your expectations for the 2nd Novel Ingredients for Infant Formula & Nutrition Summit?**

We're excited to showcase our advancements in ingredient manufacturing and compositional research at the summit. It's a valuable opportunity to share insights, explore the latest innovations in dairy-based ingredients, and engage with fellow industry leaders. We look forward to meaningful discussions that will help shape the future of infant nutrition.

Don't Miss Tim's Exclusive Session On Conference Day One:

'Innovation by Compositional Analyses': Novel Communication Opportunities by Addressing Bioactive Ingredient Composition & Preclinical Functionality